Pegcetacoplan resulted in a significantly greater reduction in proteinuria than placebo among patients with C3 glomerulopathy or primary immune-complex MPGN. (Funded by Apellis Pharmaceuticals and Sobi Swedish Orphan Biovitrum; VALIANT ClinicalTrials.gov number, NCT05067127.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Gema Ariceta
Yahsou Delmas
Christoph Licht
New England Journal of Medicine
University of Toronto
Imperial College London
Istituti di Ricovero e Cura a Carattere Scientifico
Building similarity graph...
Analyzing shared references across papers
Loading...
Ariceta et al. (Wed,) studied this question.
www.synapsesocial.com/papers/693624984fa91c937236bff5 — DOI: https://doi.org/10.1056/nejmoa2501510